Indian pharma major Lupin (BSE: 500257) has suffered a major drop in share price after the US Food and Drug Administration issued the firm with a warning letter related to two of its manufacturing sites.
The warning letter, which cites apparent violations of good manufacturing practice (GMP) at the firm’s Goa and Indore units, comes after Lupin was put on notice about quality lapses earlier in the year.
While the company said in a stock exchange filing that it had responded to those issues, the letter indicates the FDA was not satisfied with the response.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze